Intradermal Rabies Vaccine Dosing
The intradermal (ID) dose of rabies vaccine is 0.1 mL per injection site, NOT the standard 1.0 mL intramuscular dose.
Critical Distinction: ID vs IM Routes
The provided guidelines 1 and FDA drug label 2 exclusively describe intramuscular (IM) administration at 1.0 mL per dose. These sources do not endorse or provide official intradermal dosing recommendations for the United States.
However, intradermal administration uses one-tenth the volume: 0.1 mL per site 3, 4, 5, 6, 7. This is a well-established, WHO-endorsed approach used globally for cost-effectiveness.
Intradermal Dosing Regimens (Based on Research Evidence)
Pre-Exposure Prophylaxis (ID Route)
- Standard regimen: 0.1 mL ID at 2 sites on days 0 and 7 (or days 0 and 21) 4, 5
- Alternative: 0.1 mL ID at single site on days 0,7, and 21-28
- All subjects achieve protective antibody levels (>0.5 IU/mL) with these regimens 4, 5, 7
Post-Exposure Prophylaxis (ID Route)
- Previously unvaccinated: 0.1 mL ID at 4 sites on day 0, then 0.1 mL ID at 2 sites on day 7 6
- Previously vaccinated: 0.1 mL ID at single site on days 0 and 3 3
- WHO-endorsed regimen: 0.1 mL ID on days 0 and 3 for previously immunized individuals 3
Booster Doses (ID Route)
- Single booster: 0.1 mL ID at one site is sufficient to produce adequate anamnestic response 3, 4
- Antibody levels persist >180 days after ID booster 3
- Avidity maturation occurs after first ID booster dose 3
Important Caveats
U.S. FDA-approved dosing remains 1.0 mL IM only 2. The ACIP guidelines 1 specify:
- Post-exposure (unvaccinated): 1.0 mL IM on days 0,3,7,14 (4-dose series)
- Post-exposure (previously vaccinated): 1.0 mL IM on days 0 and 3
- Pre-exposure: 1.0 mL IM on days 0,7, and 21 or 28
The intradermal route at 0.1 mL is used extensively worldwide and supported by robust research 3, 4, 5, 6, 7, demonstrating:
- Non-inferior immunogenicity to IM route
- 90% vaccine volume savings
- Safe with only mild local reactions
- Adequate antibody response in >95-100% of recipients
Administration Site for ID
- Deltoid region preferred in adults
- Anterolateral thigh acceptable in children
- Never use gluteal area (applies to both IM and ID routes)
Key Pitfall
Do not confuse ID dosing (0.1 mL) with IM dosing (1.0 mL). Using 1.0 mL intradermally would be excessive and inappropriate. Conversely, using 0.1 mL intramuscularly would be inadequate for the IM route.